Why the study?
Cases of vaccine-associated myocarditis have been infrequently reported, most recently with the COVID-19 mRNA vaccine.
This case report highlights a rare instance of acute perimyocarditis occurring after a COVID-19 mRNA vaccine booster in a healthy adolescent.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to monitor for rare perimyocarditis post-booster in adolescents; hypothesis-generating and requires confirmation in larger studies.
Perimyocarditis is the inflammation of the pericardium along with the myocardium. Presentation is similar to acute pericarditis, but it is associated with myocardial damage, leading to an elevation in serum troponin and a left ventricular dysfunction (manifested as an ejection fraction of less than 55 percent). Perimyocarditis is mostly managed like acute myocarditis. Etiology is generally idiopathic and likely secondary to viral infections. Cases of vaccine-associated myocarditis have been infrequently reported in past, most recently with the COVID-19 mRNA vaccine. We present a rare case of a young healthy adolescent male who developed perimyocarditis after the first booster dose of the COVID-19 mRNA vaccine.
No takes yet. Share an insight, caveat, or question.
Phogat et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: